Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 13/20 | 0.46 |
| ▸ | UGCG | Q16739 | 4/20 | 0.42 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | ACACA | Q13085 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19894585 | 1.00 | ACACB (0.46) | ACACBUGCGDEGS1NR3C1NOTUM | |
| SCHEMBL18094914 | 1.00 | ACACB (0.46) | ACACBUGCGDEGS1NR3C1NOTUM | |
| SCHEMBL16695266 | 1.00 | ACACB (0.46) | ACACBUGCGDEGS1NR3C1NOTUM | |
| SCHEMBL16695165 | 1.00 | ACACB (0.46) | ACACBUGCGDEGS1NR3C1NOTUM | |
| SCHEMBL19894464 | 1.00 | ACACB (0.46) | ACACBUGCGDEGS1NR3C1NOTUM | |
| SCHEMBL16695267 | 1.00 | ACACB (0.46) | ACACBUGCGDEGS1NR3C1NOTUM | |
| SCHEMBL18094916 | 1.00 | ACACB (0.46) | ACACBUGCGDEGS1NR3C1NOTUM | |
| SCHEMBL20840853 | 0.92 | ACACB (0.46) | ACACBACACA | |
| SCHEMBL16695412 | 0.92 | ACACB (0.46) | ACACBNOTUMACACA | |
| SCHEMBL19894567 | 0.92 | ACACB (0.46) | ACACBNOTUMACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358932-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358932-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | GBA1, UGCG, GBA2 | ACACB 71/4885UGCG 2/4885DEGS1 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.